CN113230224B - 一种比沙可啶片剂及其制备方法 - Google Patents
一种比沙可啶片剂及其制备方法 Download PDFInfo
- Publication number
- CN113230224B CN113230224B CN202110536425.4A CN202110536425A CN113230224B CN 113230224 B CN113230224 B CN 113230224B CN 202110536425 A CN202110536425 A CN 202110536425A CN 113230224 B CN113230224 B CN 113230224B
- Authority
- CN
- China
- Prior art keywords
- bisacodyl
- parts
- tablet
- content
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 title claims abstract description 127
- 229960000503 bisacodyl Drugs 0.000 title claims abstract description 127
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 229920002472 Starch Polymers 0.000 claims abstract description 53
- 239000008107 starch Substances 0.000 claims abstract description 53
- 235000019698 starch Nutrition 0.000 claims abstract description 53
- 229940069521 aloe extract Drugs 0.000 claims abstract description 37
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 36
- 244000062793 Sorghum vulgare Species 0.000 claims abstract description 27
- 235000019713 millet Nutrition 0.000 claims abstract description 27
- 239000011736 potassium bicarbonate Substances 0.000 claims abstract description 27
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims abstract description 27
- 235000015497 potassium bicarbonate Nutrition 0.000 claims abstract description 27
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims abstract description 27
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims abstract description 26
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000001630 malic acid Substances 0.000 claims abstract description 26
- 235000011090 malic acid Nutrition 0.000 claims abstract description 26
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 26
- 239000011734 sodium Substances 0.000 claims abstract description 26
- 235000000832 Ayote Nutrition 0.000 claims abstract description 25
- 235000009854 Cucurbita moschata Nutrition 0.000 claims abstract description 25
- 240000001980 Cucurbita pepo Species 0.000 claims abstract description 25
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 claims abstract description 25
- 239000000843 powder Substances 0.000 claims abstract description 25
- 235000015136 pumpkin Nutrition 0.000 claims abstract description 25
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 23
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 23
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract description 23
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 23
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 claims abstract description 23
- 229960000511 lactulose Drugs 0.000 claims abstract description 23
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000000463 material Substances 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims description 58
- 238000003756 stirring Methods 0.000 claims description 46
- 238000002156 mixing Methods 0.000 claims description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 239000008187 granular material Substances 0.000 claims description 20
- 238000010438 heat treatment Methods 0.000 claims description 20
- 239000011248 coating agent Substances 0.000 claims description 16
- 238000000576 coating method Methods 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 16
- 238000001816 cooling Methods 0.000 claims description 8
- 239000000839 emulsion Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 238000000227 grinding Methods 0.000 claims description 8
- 239000005457 ice water Substances 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 8
- 239000012798 spherical particle Substances 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 2
- 229940099690 malic acid Drugs 0.000 claims description 2
- 239000002075 main ingredient Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 abstract description 23
- 230000000694 effects Effects 0.000 abstract description 10
- 230000000857 drug effect Effects 0.000 abstract description 4
- 238000000465 moulding Methods 0.000 abstract description 3
- 238000004080 punching Methods 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 56
- 241000699670 Mus sp. Species 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 230000013872 defecation Effects 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 208000019025 Hypokalemia Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000002924 anti-infective effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000004347 intestinal mucosa Anatomy 0.000 description 3
- 208000024896 potassium deficiency disease Diseases 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000010924 continuous production Methods 0.000 description 2
- 239000002662 enteric coated tablet Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000008141 laxative Substances 0.000 description 2
- 230000002475 laxative effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 241001116389 Aloe Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 239000001415 potassium malate Substances 0.000 description 1
- 235000011033 potassium malate Nutrition 0.000 description 1
- SVICABYXKQIXBM-UHFFFAOYSA-L potassium malate Chemical compound [K+].[K+].[O-]C(=O)C(O)CC([O-])=O SVICABYXKQIXBM-UHFFFAOYSA-L 0.000 description 1
- 229940070017 potassium supplement Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110536425.4A CN113230224B (zh) | 2021-05-17 | 2021-05-17 | 一种比沙可啶片剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110536425.4A CN113230224B (zh) | 2021-05-17 | 2021-05-17 | 一种比沙可啶片剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113230224A CN113230224A (zh) | 2021-08-10 |
CN113230224B true CN113230224B (zh) | 2022-04-22 |
Family
ID=77134800
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110536425.4A Active CN113230224B (zh) | 2021-05-17 | 2021-05-17 | 一种比沙可啶片剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113230224B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5843479A (en) * | 1993-02-26 | 1998-12-01 | The Procter & Gamble Company | Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3010007B2 (ja) * | 1995-05-22 | 2000-02-14 | ビオフェルミン製薬株式会社 | 配合下剤 |
-
2021
- 2021-05-17 CN CN202110536425.4A patent/CN113230224B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5843479A (en) * | 1993-02-26 | 1998-12-01 | The Procter & Gamble Company | Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery |
Non-Patent Citations (1)
Title |
---|
流化床颗粒包衣法制备替米沙坦氢氯噻嗪片;陈浩等;《中国现代应用药学》;20150531;第32卷(第5期);第556-560页 * |
Also Published As
Publication number | Publication date |
---|---|
CN113230224A (zh) | 2021-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020113811A1 (zh) | 含烟酰胺单核苷酸的生物高分子纳米球及其制备方法与应用 | |
CN102357088A (zh) | 盐酸二甲双胍肠溶片 | |
CA1276560C (en) | Process for producing a sustained release ibuprofen preparation | |
CN109044988A (zh) | 一种盐酸二甲双胍药物组合物及其制备方法和应用 | |
CN113230224B (zh) | 一种比沙可啶片剂及其制备方法 | |
WO2012136125A1 (zh) | 由溴代双氢青蒿素和Fe2+剂组成的复方双释胶囊制剂 | |
CN108938601A (zh) | 一种盐酸二甲双胍肠溶缓释微丸及其制备方法 | |
US20100272794A1 (en) | Pharmaceutical composition of memantine | |
KR20210042041A (ko) | 페놀라민 b형 결정, 제조 방법과 그의 조성물 및 용도 | |
CN109045034B (zh) | 一种盐酸莫西沙星药物组合物及其制备方法和应用 | |
CN102973541A (zh) | 一种l-瓜氨酸在制备抗胃溃疡药物中的应用 | |
CN112587493A (zh) | 一种双氯芬酸钠的口服缓释制剂及其制备方法 | |
CN107868009A (zh) | 一种酒石酸美托洛尔晶体及含该晶体的药物组合物及其制备方法 | |
CN105726491A (zh) | 治疗肠胃疾病的聚六亚甲基胍药物及其制备方法和应用 | |
CN105168183A (zh) | 一种格列齐特缓释胶囊及其制备方法和应用 | |
CN105902513B (zh) | 一种肠溶型金霉素微丸预混剂及其制备方法 | |
CN101081227B (zh) | 甘草酸二铵的组合物 | |
CN100531741C (zh) | 异甘草酸镁的口服制剂及其制备方法 | |
CN113081987B (zh) | 一种氟胞嘧啶片剂及其制备方法 | |
CN101693019A (zh) | 畜禽用盐酸多西环素口腔崩解片及其制备方法 | |
CN112315929B (zh) | 一种四层包衣系统美沙拉嗪肠溶片的组合物及其制备方法 | |
CN107616977A (zh) | 一种治疗偏头痛的复方制剂及其制备方法 | |
WO2021179319A1 (zh) | 一种含水解硫酸软骨素的用于防治骨关节病的组合物 | |
CN109381476B (zh) | 一种减肥的药物组合物 | |
CN106822015A (zh) | 乙酰唑胺缓释片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Bisacodine tablet and its preparation method Effective date of registration: 20230105 Granted publication date: 20220422 Pledgee: Zijin Trust Co.,Ltd. Pledgor: CPU-PHARMA Co.,Ltd. Registration number: Y2022980029390 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20220422 Pledgee: Zijin Trust Co.,Ltd. Pledgor: CPU-PHARMA Co.,Ltd. Registration number: Y2022980029390 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A Bisacodine Tablet and Its Preparation Method Granted publication date: 20220422 Pledgee: Jiangsu Zijin Rural Commercial Bank Co.,Ltd. Gulou sub branch Pledgor: CPU-PHARMA Co.,Ltd. Registration number: Y2024980008966 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |